$0.0549
In chiusura: Oct 27, 7:59 PM EDT
$0.0579
0.003005.46%
After hour: Oct 27, 7:59 PM EDT
Comments
Loading...
Stime degli utili, EPS e fatturato
Adaptimmune Therapeutics PLC DR segnala gli utili su base trimestrale. Questi report sugli utili trimestrali offrono agli investitori uno sguardo ai risultati finanziari di un'azienda per un periodo di 3 mesi. I report sugli utili includono quasi sempre i risultati EPS e i ricavi.
Data degli utili
nov 21
Stima EPS
$-0.110
Stima dei ricavi trimestrali
$10.65M
Ricavi annuali
–
Analizza lo storico degli utili di Adaptimmune Therapeutics PLC DR utilizzando ordinamenti e filtri avanzati.
Get Alert | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
ADAP | Adaptimmune Therapeutics | -$0.07 | -$0.11 | — | — | $40.90M | $10.65M | — | — | 11/21/2025 | |
ADAP | Adaptimmune Therapeutics | $0.04 | -$0.14 | -$0.02 | 85.71% | $128.23M | $7.94M | $13.68M | 72.22% | 08/13/2025 | |
ADAP | Adaptimmune Therapeutics | -$0.03 | -$0.17 | -$0.03 | 82.35% | $5.68M | $6.55M | $7.29M | 11.22% | 05/13/2025 | |
ADAP | Adaptimmune Therapeutics | -$0.24 | -$0.15 | -$0.30 | -100.00% | $231.00K | $8.42M | $3.22M | -61.73% | 03/20/2025 | |
ADAP | Adaptimmune Therapeutics | -$0.18 | -$0.13 | -$0.07 | 46.15% | $7.32M | $11.17M | $40.90M | 266.17% | 11/13/2024 | |
ADAP | Adaptimmune Therapeutics | -$0.12 | -$0.08 | $0.24 | 400.00% | $5.13M | $38.48M | $128.23M | 233.24% | 08/12/2024 | |
ADAP | Adaptimmune Therapeutics | $0.00 | -$0.10 | -$0.18 | -80.00% | $47.60M | $10.73M | $5.68M | -47.08% | 05/15/2024 | |
ADAP | Adaptimmune Therapeutics | -$0.18 | -$0.10 | -$0.24 | -140.00% | $11.03M | $20.47M | $231.00K | -98.87% | 03/06/2024 | |
ADAP | Adaptimmune Therapeutics | -$0.24 | -$0.15 | -$0.18 | -20.00% | $7.01M | $10.28M | $7.32M | -28.80% | 11/08/2023 | |
ADAP | Adaptimmune Therapeutics | -$0.05 | -$0.13 | -$0.12 | 7.69% | $5.54M | $8.78M | $5.13M | -41.57% | 08/09/2023 | |
ADAP | Adaptimmune Therapeutics | -$0.05 | -$0.14 | $0.00 | 100.00% | $3.58M | $4.93M | $47.60M | 865.54% | 05/12/2023 | |
ADAP | Adaptimmune Therapeutics | -$0.04 | -$0.25 | -$0.18 | 28.00% | $1.42M | $4.12M | $11.03M | 167.67% | 03/06/2023 | |
ADAP | Adaptimmune Therapeutics | -$0.30 | -$0.24 | -$0.24 | 0.00% | $1.20M | $4.04M | $7.01M | 73.44% | 11/08/2022 | |
ADAP | Adaptimmune Therapeutics | -$0.24 | -$0.25 | -$0.28 | -12.00% | $3.10M | $6.00M | $5.54M | -7.70% | 08/04/2022 | |
ADAP | Adaptimmune Therapeutics | -$0.04 | -$0.22 | -$0.32 | -45.45% | $434.00K | $3.29M | $3.58M | 8.66% | 05/09/2022 | |
ADAP | Adaptimmune Therapeutics | -$0.24 | $0.14 | -$0.25 | -278.57% | $1.50M | $96.45M | $1.42M | -98.53% | 03/14/2022 | |
ADAP | Adaptimmune Therapeutics | -$0.24 | -$0.26 | -$0.30 | -15.38% | $1.19M | $1.37M | $1.20M | -12.19% | 11/04/2021 | |
ADAP | Adaptimmune Therapeutics | -$0.24 | -$0.24 | -$0.24 | 0.00% | $502.00K | $1.36M | $3.10M | 127.57% | 08/09/2021 | |
ADAP | Adaptimmune Therapeutics | -$0.04 | -$0.25 | -$0.24 | 4.00% | $761.00K | $1.83M | $434.00K | -76.28% | 05/06/2021 | |
ADAP | Adaptimmune Therapeutics | -$0.05 | -$0.23 | -$0.24 | -4.35% | $728.00K | $1.98M | $1.50M | -24.14% | 02/25/2021 |
Adaptimmune Therapeutics PLC DR (ADAP) Guadagno per azione
Importo a sorpresa sugli utili trimestrali
| Trimestre fiscale | Data segnalata | EPS effettivo | EPS stimato | Sorpresa% |
|---|---|---|---|---|
| Q2 | 2025-08-13 | $-0.02 | $-0.14 | 85.7 % |
| Q1 | 2025-05-13 | $-0.03 | $-0.17 | 82.3 % |
| Q4 | 2025-03-20 | $-0.30 | $-0.15 | -100.0 % |
| Q3 | 2024-11-13 | $-0.07 | $-0.13 | 46.2 % |
Adaptimmune Therapeutics PLC DR (ADAP) Entrate
Importo sorpresa sulle entrate trimestrali
| Trimestre fiscale | Data segnalata | Entrate effettive | Entrate stimate | Sorpresa% |
|---|---|---|---|---|
| Q2 | 2025-08-13 | $13.68M | $7.94M | 72.2 % |
| Q1 | 2025-05-13 | $7.29M | $6.55M | 11.2 % |
| Q4 | 2025-03-20 | $3.22M | $8.42M | -61.7 % |
| Q3 | 2024-11-13 | $40.90M | $11.17M | 266.2 % |
FAQ
Quando Adaptimmune Therapeutics PLC DR (NASDAQ:ADAP) riporterà gli utili?
Si prevede che Adaptimmune Therapeutics PLC DR (ADAP) fornisca risultati il novembre 21, 2025. Gli ultimi risultati sono stati pubblicati il agosto 13, 2025 per il Q2.
Quali sono stati gli ultimi utili per azione (EPS) di Adaptimmune Therapeutics PLC DR (NASDAQ:ADAP)?
L'EPS effettivo era $-0.02, che superato la stima di $-0.14.
Quali sono state le entrate di Adaptimmune Therapeutics PLC DR (NASDAQ:ADAP)?
Le entrate effettive sono state $13.7M, che superato la stima di $7.9M.
Sfoglia stime sugli utili, EPS e ricavi su tutte le azioni.